tirzepatide trial sign up Shows Superior Weight Loss Over Semaglutide in Phase 3 What to Know Before Starting

When treatment regimens are streamlined and personalized, tracking becomes easier and more accurate

Findings Participants and Intervention: Between October 5, 2018, and February 1, 2019, 304 individuals were randomly assigned to either receive semaglutide 2.4 mg (n = 152) or placebo (n = 152) and were encompassed in the comprehensive analysis set (comprising all randomized individuals as per the intention-to-treat principle)

Oz and News NY 1

Dreischer P, Duszenko M, Stein J, Wieder T

Most insurance companies will also cover treatment at this level, though some require documentation of prior weight loss attempts

Communication with the patients care team, including primary care providers and endocrinologists, is essential